Samuel Funt, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    AstraZeneva
    Date added:
    Date updated:
    05/16/2022
  • Attribution:
    Self
    Type of financial relationship:
    Scientific Study or Trial (Oncology)
    Ineligible company:
    Genetech/Roche
    Date added:
    Date updated:
    05/16/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    05/16/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Oncology)
    Ineligible company:
    Urogen Pharma
    Date added:
    Date updated:
    05/16/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Oncology)
    Ineligible company:
    Allogene Therapeutics
    Date added:
    Date updated:
    05/16/2022
  • Attribution:
    Self
    Type of financial relationship:
    Investment Interest (Oncology)
    Ineligible company:
    Neogene Therapeutics
    Date added:
    Date updated:
    05/16/2022
Return to Update Series (2023) Lesson 10: The Evolving Management of Testicular Seminoma